These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 19947038

  • 21. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
    Gronlund B, Hansen HH, Høgdall C, Engelholm SA.
    Cancer; 2002 Oct 15; 95(8):1656-62. PubMed ID: 12365013
    [Abstract] [Full Text] [Related]

  • 22. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.
    Rodriguez M, Rose PG.
    Gynecol Oncol; 2001 Nov 15; 83(2):257-62. PubMed ID: 11606080
    [Abstract] [Full Text] [Related]

  • 23. A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma.
    Rose PG, Smrekar M, Haba P, Visser C, Beeler JF.
    Gynecol Oncol; 2005 Dec 15; 99(3):714-9. PubMed ID: 16112177
    [Abstract] [Full Text] [Related]

  • 24. Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature.
    Traina TA, Sabbatini P, Aghajanian C, Dupont J.
    Gynecol Oncol; 2004 Oct 15; 95(1):235-41. PubMed ID: 15385138
    [Abstract] [Full Text] [Related]

  • 25. A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma.
    Elkas JC, Winter WE, Chernofsky MR, Sunde J, Bidus MA, Bernstein S, Rose GS.
    Gynecol Oncol; 2007 Feb 15; 104(2):422-7. PubMed ID: 16996118
    [Abstract] [Full Text] [Related]

  • 26. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Herzog TJ, Powell MA, Rader JS, Gibb RK, Lippmann L, Coleman RL, Mutch DG.
    Gynecol Oncol; 2008 Dec 15; 111(3):467-73. PubMed ID: 18834619
    [Abstract] [Full Text] [Related]

  • 27. A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum.
    Brown JV, Peters WA, Rettenmaier MA, Karlan BY, Dillman RA, Smith MR, Drescher CW, Micha JP.
    Gynecol Oncol; 2000 Dec 15; 79(3):495-8. PubMed ID: 11104627
    [Abstract] [Full Text] [Related]

  • 28. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
    Fiorica J, Holloway R, Ndubisi B, Orr J, Grendys E, Boothby R, DeCesare S, LaPolla J, Hoffman M, Patel J.
    Gynecol Oncol; 2002 Apr 15; 85(1):89-94. PubMed ID: 11925125
    [Abstract] [Full Text] [Related]

  • 29. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stähle A, Jackisch C, Hardy-Bessard AC, Möbus V, Quaas J, Richter B, Schröder W, Geay JF, Lück HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E, AGO-OVAR, GINECO.
    J Natl Cancer Inst; 2006 Aug 02; 98(15):1036-45. PubMed ID: 16882940
    [Abstract] [Full Text] [Related]

  • 30. Duration of chemotherapy with topotecan influences survival in recurrent ovarian cancer: a meta-analysis.
    Möbus V, Kieback DG, Kaubitzsch SK.
    Anticancer Res; 2007 Aug 02; 27(3B):1581-7. PubMed ID: 17595779
    [Abstract] [Full Text] [Related]

  • 31. [Early results of topotecan therapy in patients with recurrent ovarian cancer].
    Lehoczky O, Bagaméri A, Lehoczky G, Pulay T.
    Orv Hetil; 2002 Apr 21; 143(16):825-8. PubMed ID: 12053883
    [Abstract] [Full Text] [Related]

  • 32. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies.
    Temkin SM, Yamada SD, Fleming GF.
    Gynecol Oncol; 2010 Jun 21; 117(3):473-6. PubMed ID: 20347480
    [Abstract] [Full Text] [Related]

  • 33. Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer.
    Gelderblom H, Sparreboom A, de Jonge MJ, Loos WJ, Wilms E, Mantel MA, Hennis B, Camlett I, Verweij J, van der Burg ME.
    Br J Cancer; 2001 Oct 19; 85(8):1124-9. PubMed ID: 11710824
    [Abstract] [Full Text] [Related]

  • 34. Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
    Prince HM, Rischin D, Quinn M, Allen D, Planner R, Neesham D, Gates P, Davison J.
    Gynecol Oncol; 2001 May 19; 81(2):216-24. PubMed ID: 11330952
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.
    Gordon AN, Hancock KC, Matthews CM, Messing M, Stringer CA, Doherty MG, Teneriello M.
    Gynecol Oncol; 2002 Apr 19; 85(1):129-35. PubMed ID: 11925132
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.